Juhl Rebecca C, Roddy Julianna V F, Wang Tzu-Fei, Li Junan, Elefritz Jessica L
a Department of Pharmacy , The Ohio State University Wexner Medical Center and Arthur G. James Cancer Hospital and Richard J Solove Research Institute , Columbus , OH , USA.
b Division of Hematology, Department of Internal Medicine , The Ohio State University Wexner Medical Center and Arthur G. James Cancer Hospital and Richard J Solove Research Institute , Columbus , OH , USA.
Leuk Lymphoma. 2018 Oct;59(10):2377-2382. doi: 10.1080/10428194.2018.1434882. Epub 2018 Feb 9.
Aminocaproic acid is frequently used in patients with hematologic malignancy that present with thrombocytopenia with or without hemorrhage. We conducted a retrospective study to evaluate the safety of aminocaproic acid in 109 patients with hematologic malignancies. Patients were included if aminocaproic acid had been administered for at least 24 hours for the prevention or treatment of thrombocytopenic hemorrhage. Our primary outcome was thromboembolic complications defined as arterial or venous thrombotic events objectively confirmed by imaging studies. Thromboembolic complications occurred in five patients (4.6%) and all were venous thromboses. Other than the underlying malignancy, these patients also had many concurrent risk factors including indwelling central venous catheters, which could have contributed to thromboses. In conclusion, in our population of patients with a variety of hematological malignancies, aminocaproic acid does not appear to be associated with a high incidence of thromboembolic complications.
氨基己酸常用于患有血小板减少症（伴或不伴出血）的血液系统恶性肿瘤患者。我们进行了一项回顾性研究，以评估109例血液系统恶性肿瘤患者使用氨基己酸的安全性。如果氨基己酸已被用于预防或治疗血小板减少性出血至少24小时，则纳入患者。我们的主要结局是血栓栓塞并发症，定义为经影像学研究客观证实的动脉或静脉血栓形成事件。5例患者（4.6%）发生了血栓栓塞并发症，均为静脉血栓形成。除了潜在的恶性肿瘤外，这些患者还有许多并发的危险因素，包括留置中心静脉导管，这可能导致了血栓形成。总之，在我们这群患有各种血液系统恶性肿瘤的患者中，氨基己酸似乎与血栓栓塞并发症的高发生率无关。
